Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Naresh Chandan

Internal Medicine Kankakee, IL Doctor of Osteopathy

NPI 1811094550 CMS profile 82630

401 N Wall St Ste 102, Kankakee, IL 60901

Open in the dashboard

General payments

$9,248

464 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Naresh Chandan of Kankakee, IL is reported in the CMS Open Payments database as having received $9,248 across 464 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,791 72
2024 General $1,677 79
2023 General $1,657 73
2022 General $1,065 61
2021 General $1,605 90
2020 General $527 33
2019 General $926 56

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Naresh Chandan
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Naresh Chandan were reported at $1,791. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Naresh Chandan Internal Medicine median Middle half National median
2019 $926 $159 $48–$570 $163
2020 $527 $119 $33–$402 $114
2021 $1,605 $135 $37–$521 $132
2022 $1,065 $141 $42–$496 $149
2023 $1,657 $149 $45–$519 $160
2024 $1,677 $154 $47–$537 $164
2025 $1,791 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,132 69 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $841 32 payments
  3. Amgen Inc. $752 39 payments
  4. Lilly USA, LLC $692 47 payments
  5. AstraZeneca Pharmaceuticals LP $618 21 payments
  6. GlaxoSmithKline, LLC. $569 35 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $423 22 payments
  8. Janssen Pharmaceuticals, Inc $413 14 payments
  9. AbbVie, Inc. $383 20 payments
  10. Pfizer Inc. $365 19 payments
  11. Other $3,058 146 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,952 460 payments
  2. Consulting Fee $175 1 payment
  3. Education $121 3 payments
Products named General payments · program years 2019–2025
  1. Ozempic $713 50 payments
  2. XIFAXAN $423 22 payments
  3. XARELTO $413 14 payments
  4. JARDIANCE Diabetes $413 13 payments
  5. JARDIANCE Diabetes $328 13 payments
  6. Repatha $299 20 payments
  7. Prolia $294 10 payments
  8. FARXIGA $272 6 payments
  9. TRELEGY ELLIPTA $257 23 payments
  10. Otezla $254 15 payments
  11. Other $8,129 444 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 169 drugs

Part D claims

11,171

Median for Internal Medicine: 777

Drug cost

$562,919

Median for Internal Medicine: $73,373

Branded share of claims

17.2%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 72 $95,724
Jardiance Empagliflozin Brand 50 $64,561
Eliquis Apixaban Brand 64 $43,728
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 39 $34,372
Xarelto Rivaroxaban Brand 24 $25,170
Vascepa Icosapent Ethyl Brand 69 $22,933
Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog Brand 49 $15,492
Trulicity Dulaglutide Brand 14 $13,856
Farxiga Dapagliflozin Propanediol Brand 20 $13,790
Autoshield Duo Pen Needle Pen Needle,dual Safety,diabetc Brand 111 $10,700

The 10 drugs with the highest cost, of 169 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$107,500

Of which drugs: $8,519

Medicare patients

333

Average age 72

Services billed

1,283

111 women, 222 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 40%
Ischemic heart disease 31%
Diabetes 29%
Chronic kidney disease 27%
Heart failure 19%
Depression 19%
Atrial fibrillation 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 59 60 $4,889
Pcv20 vaccine im 90677 Office 12 12 $3,487

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 31 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $296
$296 50 —
Ozempic
  • Novo Nordisk Inc $85
$85 72 —
MOUNJARO
  • Lilly USA, LLC $74
$74 — —
LOKELMA
  • AstraZeneca Pharmaceuticals LP $73
$73 — —
AMYVID
  • Lilly USA, LLC $67
$67 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 31 with Patron

Records

464 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record